Tykerb approved for metastatic breast cancer treatment in combination with letrozole - MPR

Links shared publicly online about this topic.

  • 1,413
    total visits

Tykerb approved for metastatic breast cancer treatment in combination with letrozole - MPR

empr.com

GlaxoSmithKline announced that the FDA has approved Tykerb (lapatinib tablets) in combination with letrozole (Femara, from Novartis) as a first-line, all-oral regimen for the treatment of postmenopausal women with hormone receptor (HR) positive metastatic breast cancer that overexpresses the HER2 receptor.

View full resource at empr.com

Tags: Breast Cancer, Breast Cancer Medication, Metastatic Breast Cancer, Women's Health, FDA, Femara, Novartis, GlaxoSmithKline

  • Share

Most Recently Shared on February 1, 2010 at 4:03 pm By:

eMPR MPR

MPR News: Tykerb approved for metastatic breast cancer treatment in combination with letrozole: GlaxoSmithKline an... http://bit.ly/bXPrOd

2 years ago...

GSK's TYKERB(R) Receives Accelerated Approval For First-Line Combination Treatment Of Metastatic Breast Cancer

medicalnewstoday.com — “GlaxoSmithKline (NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-lineView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on February 2, 2010 at 2:10 pm By:

mnt_breastcance MNT Breast Cancer Health News

GSK's TYKERB(R) Receives Accelerated Approval For First-Line Combination Treatment Of Metastatic Breast Cancer http://mnt.to/3x4y

2 years ago...

FDA approves lapatinib plus letrozole for HER-2–positive, HR-positive, metastatic breast cancer | HemOncToday

hemonctoday.com — “The FDA has announced its accelerated approval of the combination of lapatinib plus the aromatase inhibitor letrozole for the treatment of hoView full resource at hemonctoday.com

  • View Related
  • Share

Most Recently Shared on February 1, 2010 at 3:39 pm By:

HemOncToday HemOnc Today Oncology and Health News

FDA approves lapatinib plus letrozole for HER-2–positive, HR-positive, metastatic breast cancer http://ow.ly/12Act

2 years ago...

GSK’s TYKERB receives accelerated approval for first-line combination treatment of metastatic breast cancer

us.gsk.com — “not namedView full resource at us.gsk.com

  • View Related
  • Share

Most Recently Shared on February 1, 2010 at 2:33 pm By:

eyeonfda eyeonfda Pharma and Health Lawyer

GSK’s TYKERB receives accelerated approval for first-line combination treatment of metastatic breast cancer - http://ow.ly/12ytk

2 years ago...

Advertisement